PHARMACYTE BIOTECH, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
PHARMACYTE BIOTECH, INC. (PMCB) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$4.19 million for the 9-month period ending 2023-01-31, per its 10-Q filed 2023-03-16.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2023-03-16
- PHARMACYTE BIOTECH, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-01-31 was -$764.14K.
- PHARMACYTE BIOTECH, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-01-31 was -$811.29K.
- PHARMACYTE BIOTECH, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-10-31 was -$979.75K.
- PHARMACYTE BIOTECH, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-07-31 was -$1.03M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month |
|---|---|---|---|
| 2023-01-31 | -$764.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-16 | -$4.19M 10-Q · filed 2023-03-16 | |
| 2022-10-31 | -$3.43M 10-Q · filed 2022-12-14 | ||
| 2022-01-31 | -$811.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-16 | -$1.79M derived: sum of 2 quarters · filed 2023-03-16 | -$2.82M 10-Q · filed 2023-03-16 |
| 2021-10-31 | -$979.75K 10-Q · filed 2021-12-14 | -$2.01M 10-Q · filed 2022-12-14 | |
| 2021-07-31 | -$1.03M 10-Q · filed 2021-12-14 | ||
| 2021-01-31 | -$757.10K 10-Q · filed 2021-03-12 | -$1.71M derived: sum of 2 quarters · filed 2021-12-14 | -$2.59M derived: sum of 3 quarters · filed 2021-12-14 |
| 2020-10-31 | -$950.19K 10-Q · filed 2021-12-14 | -$1.83M derived: sum of 2 quarters · filed 2021-12-14 | |
| 2020-07-31 | -$883.94K 10-Q · filed 2021-12-14 | ||
| 2020-01-31 | -$875.31K 10-Q · filed 2021-03-12 | -$1.94M derived: sum of 2 quarters · filed 2021-03-12 | -$3.08M derived: sum of 3 quarters · filed 2021-03-12 |
| 2019-10-31 | -$1.07M 10-Q · filed 2021-03-12 | -$2.20M derived: sum of 2 quarters · filed 2021-03-12 | |
| 2019-07-31 | -$1.13M 10-Q · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |